Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today announced the appointment of Josh Hexter as Interim Chief Executive Officer effective September 1, 2026 and Rami Aviram as Chief Financial Officer effective November 1, 2026.

Hexter succeeds Mark Grant, who has chosen to leave Lifeward to pursue other opportunities after leading the development and implementation of the Company’s current commercial strategy. Grant will serve as a consultant with the Company through September 30, 2026 to work closely with Hexter and the leadership team to ensure a smooth transition.

Lifeward enters this leadership transition with growing commercial momentum and a strategy focused on scaling its rehabilitation business through its established reimbursement infrastructure and capital-efficient distribution model. In the second quarter of 2026, revenue increased 16% year-over-year to $6.6 million, the Company’s strongest quarterly revenue performance since the fourth quarter of 2024, with ReWalk® Personal Exoskeleton sales increasing 13% and AlterG® product and service revenue increasing 25%.